ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KYNB vs MCRB // FREE CASH FLOW YIELD

Kyntra Bio Inc. (NASDAQ) VS. Seres Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: KYNB 2 — MCRB 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYNB VS. MCRB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KYNB MCRB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 91.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE — 4.42% — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin 68.00% 68.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 5/9 -1.00 MCRB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 28.4 26.3 +2.10 KYNB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $18.5M $17.8M $725.2K KYNB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KYNB REV MCRB REV KYNB GROSS % MCRB GROSS % KYNB FCF MCRB FCF
FY 2025 $6.4M $789.0K 91.4% — -$4.8M $865.0K
FY 2024 $29.6M $339.7M 47.5% — -$138.3M -$149.0M
FY 2023 $46.8M $546.3M — — -$315.0M -$117.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYNB // BETA —
MCRB // BETA —